Puma Biotechnology (PBYI) Set to Post Earnings on Thursday

Puma Biotechnology (NASDAQ:PBYI) will likely be posting its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Puma Biotechnology to announce earnings of $0.09 per share and revenue of $57.50 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Puma Biotechnology (NASDAQ:PBYI) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $0.19 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.15. The firm had revenue of $56.50 million during the quarter, compared to the consensus estimate of $53.00 million. Puma Biotechnology had a return on equity of 20.76% and a net margin of 11.50%. On average, analysts expect Puma Biotechnology to post $0.37 EPS for the current fiscal year and $0.14 EPS for the next fiscal year.

Puma Biotechnology Stock Performance

PBYI stock opened at $10.18 on Tuesday. Puma Biotechnology has a 1 year low of $4.57 and a 1 year high of $11.50. The stock has a market capitalization of $525.49 million, a price-to-earnings ratio of 19.58 and a beta of 1.22. The stock’s fifty day moving average is $9.83 and its two-hundred day moving average is $7.92.

Insider Buying and Selling

In related news, Director Troy Wilson sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $9.10, for a total value of $45,500.00. Following the completion of the sale, the director directly owned 54,750 shares in the company, valued at approximately $498,225. The trade was a 8.37% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Alessandra Cesano sold 62,150 shares of Puma Biotechnology stock in a transaction on Monday, September 14th. The stock was sold at an average price of $9.12, for a total transaction of $566,808.00. Following the completion of the transaction, the director owned 56,700 shares in the company, valued at $517,104. This trade represents a 52.29% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 22.20% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on PBYI shares. TD Cowen lifted their price target on Puma Biotechnology from $5.00 to $6.00 and gave the company a “hold” rating in a report on Friday, August 7th. Wall Street Zen upgraded shares of Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 15th. Finally, Weiss Ratings upgraded Puma Biotechnology from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, October 8th. One investment analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $6.00.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company focused on developing and commercializing medicines for the treatment of cancer. The company’s lead product is NERLYNX (neratinib), an oral, irreversible tyrosine kinase inhibitor designed to target HER2 and other members of the epidermal growth factor receptor family.

NERLYNX is approved in the United States for the extended adjuvant treatment of adults with early-stage, HER2-positive breast cancer following adjuvant trastuzumab-based therapy.